121 related articles for article (PubMed ID: 26637880)
1. Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.
Perrier-Trudova V; Huimin BW; Kongpetch S; Huang D; Ong P; Le Formal A; Poon SL; Siew EY; Myint SS; Gad S; Gardie B; Couvé S; Foong YM; Choudhury Y; Poh J; Ong CK; Toh CK; Ooi A; Richard S; Tan MH; Teh BT
Anticancer Res; 2015 Dec; 35(12):6639-53. PubMed ID: 26637880
[TBL] [Abstract][Full Text] [Related]
2. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
3. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
4. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
[TBL] [Abstract][Full Text] [Related]
5. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
6. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
[TBL] [Abstract][Full Text] [Related]
7. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
Yang Y; Valera V; Sourbier C; Vocke CD; Wei M; Pike L; Huang Y; Merino MA; Bratslavsky G; Wu M; Ricketts CJ; Linehan WM
Cancer Genet; 2012; 205(7-8):377-90. PubMed ID: 22867999
[TBL] [Abstract][Full Text] [Related]
8. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer.
Ahvenainen T; Lehtonen HJ; Lehtonen R; Vahteristo P; Aittomäki K; Baynam G; Dommering C; Eng C; Gruber SB; Grönberg H; Harvima R; Herva R; Hietala M; Kujala M; Kääriäinen H; Sunde L; Vierimaa O; Pollard PJ; Tomlinson IP; Björck E; Aaltonen LA; Launonen V
Cancer Genet Cytogenet; 2008 Jun; 183(2):83-8. PubMed ID: 18503824
[TBL] [Abstract][Full Text] [Related]
9. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
[TBL] [Abstract][Full Text] [Related]
10. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
Merino MJ; Torres-Cabala C; Pinto P; Linehan WM
Am J Surg Pathol; 2007 Oct; 31(10):1578-85. PubMed ID: 17895761
[TBL] [Abstract][Full Text] [Related]
11. Conventional renal cancer in a patient with fumarate hydratase mutation.
Lehtonen HJ; Blanco I; Piulats JM; Herva R; Launonen V; Aaltonen LA
Hum Pathol; 2007 May; 38(5):793-6. PubMed ID: 17270241
[TBL] [Abstract][Full Text] [Related]
12. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma.
Refae MA; Wong N; Patenaude F; Bégin LR; Foulkes WD
Nat Clin Pract Oncol; 2007 Apr; 4(4):256-61. PubMed ID: 17392716
[TBL] [Abstract][Full Text] [Related]
13. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer.
Pithukpakorn M; Wei MH; Toure O; Steinbach PJ; Glenn GM; Zbar B; Linehan WM; Toro JR
J Med Genet; 2006 Sep; 43(9):755-62. PubMed ID: 16597677
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC).
Heinritz W; Paasch U; Sticherling M; Wittekind C; Simon JC; Froster UG; Renner R
Ann Hum Genet; 2008 Jan; 72(Pt 1):35-40. PubMed ID: 17908262
[TBL] [Abstract][Full Text] [Related]
15. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
[TBL] [Abstract][Full Text] [Related]
16. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer.
Alam NA; Olpin S; Rowan A; Kelsell D; Leigh IM; Tomlinson IP; Weaver T
J Mol Diagn; 2005 Oct; 7(4):437-43. PubMed ID: 16237213
[TBL] [Abstract][Full Text] [Related]
17. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
Plevová P; Hladíková A; Tesařová M
Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
[TBL] [Abstract][Full Text] [Related]
18. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
Joseph NM; Solomon DA; Frizzell N; Rabban JT; Zaloudek C; Garg K
Am J Surg Pathol; 2015 Nov; 39(11):1529-39. PubMed ID: 26457356
[TBL] [Abstract][Full Text] [Related]
19. The syndrome of hereditary leiomyomatosis and renal cell cancer (HLRCC): The clinical features of an individual with a fumarate hydratase gene mutation.
Varol A; Stapleton K; Roscioli T
Australas J Dermatol; 2006 Nov; 47(4):274-6. PubMed ID: 17034471
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
Ha YS; Chihara Y; Yoon HY; Kim YJ; Kim TH; Woo SH; Yun SJ; Kim IY; Hirao Y; Kim WJ
Urol Int; 2013; 90(2):233-9. PubMed ID: 23295344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
